Alpha 7 nicotinic receptor agonist and positive allosteric modulators improved social and molecular deficits of MK-801 model of schizophrenia in rats

Ünal G., Bekci H., Cumaoğlu A., Yerer M. B., Arıcıoğlu F.

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, cilt.193, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 193
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.pbb.2020.172916
  • Dergi Adı: PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Animal Behavior Abstracts, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Psycinfo, Veterinary Science Database
  • Anahtar Kelimeler: A-582941, CCMI, PNU-120596, MK-801, alpha 7 nAChR, Schizophrenia, ACETYLCHOLINE-RECEPTORS, NEGATIVE SYMPTOMS, TAU PHOSPHORYLATION, COGNITIVE DEFICIT, ANIMAL-MODELS, ACTIVATION, TRIAL, PHENCYCLIDINE, PNU-120596, RODENTS
  • Erciyes Üniversitesi Adresli: Evet

Özet

Schizophrenia is a common psychiatric disease that cannot be fully treated with current antipsychotic drugs. It has shown that glutamatergic NMDA receptor antagonists such as MK-801 cause schizophrenia-like phenotype in rodents. Recent studies indicated that alpha 7 nicotinic acetylcholine receptor (nAChR) deficits contribute to schizophrenia. Enhancing its activity with agonist or positive allosteric modulators (PAMs) may be a valuable approach for treatment. The certain intracellular pathways such as Akt/Glycogen synthase kinase 3 beta (GSK-3 beta) and phosphodiesterase-4 (PDE-4)/cAMP are associated with the pathogenesis of schizophrenia. In this study, we examined the effect of alpha 7 nAChR agonists and PAMs on the behavioral and molecular phenotype of schizophrenia in the subchronic MK-801 administered rats. Social interaction, the levels of alpha 7 nAChR, and related intracellular pathways (cAMP, PDE4A, PDE4D, p-Akt/Akt, p-GSK-3 beta/GSK-3 beta) were measured by behavioral or ELISA and western blot tests. Subchronic MK-801 administration decreased the following behaviors and increased the avoiding behaviors. However, only alpha 7 nAChR agonist (A-582941) increased the following behavior while alpha 7 nAChR agonist, PAMs (CCMI and PNU-120596), and clozapine decreased the avoiding behavior compared to MK-801. For molecular parameters, MK-801 administration decreased the alpha 7 nAChR, p-Akt/Akt, p-GSK-3 beta/GSK-3 beta expressions, and cAMP levels while it increased PDE4A, PDE4D expressions in the prefrontal cortex. Besides, MK-801 decreased the alpha 7 nAChR, p-GSK-3 beta/GSK-3 beta expressions in the hippocampus. We found clozapine, alpha 7 nAChR agonists, and PAMs reversed the molecular deficits induced by MK-801. Herein, we showed that prefrontal cortex is more sensitive to the devastating effects of subchronic MK-801 administration, especially for PDE4, in rats. In addition to clozapine, alpha 7 nAChR agonists and PAMs found to be beneficial on both social and molecular deficits induced by MK-801 in rats. We suggested that alpha 7 nAChR agonists and PAMs might be valuable approaches to treat negative symptoms of schizophrenia when unmet needs and current limitations considered in this pathology.